Quantcast
Last updated on April 16, 2014 at 12:50 EDT

Latest Anthracyclines Stories

2010-04-12 07:00:00

PRINCETON, N.J., April 12 /PRNewswire/ -- Celator Pharmaceuticals today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent covering the company's CombiPlex® technology platform (U.S. patent application 10/417,631), the basis for the company's product pipeline which includes two clinical-stage products for acute myeloid leukemia and colorectal cancer. CombiPlex is a unique approach in the development of combination...

2010-03-18 06:30:00

COLUMBIA, Md., March 18 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The abstract presents the background, rationale, and design of the DIGNITY study which is ongoing and evaluating ThermoDox in combination with hyperthermia in women with...

2010-02-17 06:30:00

COLUMBIA, Md., Feb. 17 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most...

2010-02-10 06:30:00

COLUMBIA, Md., Feb. 10 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing safety data from 120 patients enrolled in the pivotal Phase III ThermoDox® clinical trial ("HEAT" trial) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial. The DMC for the HEAT study is comprised of an independent group of medical and scientific experts who are...

2010-01-25 07:11:48

Researchers at Dana-Farber Cancer Institute have discovered a gene activity signature that predicts a high risk of cancer recurrence in certain breast tumors that have been treated with commonly used chemotherapy drugs. Despite their resistance to drugs of the anthracycline class, the breast cancers bearing this gene signature will probably still be vulnerable to other types of chemotherapy agents, say scientists in a letter to be published in Nature Medicine on its Web site and later in a...

2010-01-07 06:00:00

PRINCETON, N.J., Jan. 7 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer. Treatment with Myocet(TM) has already shown a reduced level of cardiotoxicity as compared to...

2009-12-14 10:54:00

ROCKAWAY, N.J., Dec. 14 /PRNewswire/ -- The third edition of Infusion Nursing: An Evidence-Based Approach, published by the Infusion Nurses Society (INS), includes Totect(®), the only FDA-approved treatment for anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications including daunorubicin, doxorubicin, idarubicin and epirubicin that have been used in the treatment of various types of cancer since the early 1970s.(2) According to the INS...

2009-12-08 00:30:00

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals....

2009-12-07 07:00:00

PRINCETON, N.J., Dec. 7 /PRNewswire/ -- Celator Pharmaceuticals today announced that interim safety and efficacy data from its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML) were presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana (ASH...

739066839e06178e351155745429e3ec
2009-11-01 14:52:39

Going smaller could bring better results, especially when it comes to cancer-fighting drugs. Duke University bioengineers have developed a simple and inexpensive method for loading cancer drug payloads into nano-scale delivery vehicles and demonstrated in animal models that this new nanoformulation can eliminate tumors after a single treatment. After delivering the drug to the tumor, the delivery vehicle breaks down into harmless byproducts, markedly decreasing the toxicity for the...